DIA President Ling Su On Bridging Gaps In China On The Road To Innovation: An Interview With PharmAsia News
This article was originally published in PharmAsia News
Executive Summary
DIA President Ling Su has a unique perspective on the Chinese market, having served in senior R&D positions with industry – most recently at Novartis China – and as a regulator, including stints in China’s Ministry of Health and as a visiting scientist with U.S. FDA. He recently sat down with PharmAsia News to discuss innovation and the evolution taking place in China.
You may also be interested in...
Meet China’s New Innovators: Hua Medicine Looks To Take Flight With U.S. Venture Backing (Part 1)
When multinational pharmaceutical companies began to establish R&D facilities in China a decade ago, they counted on Chinese returnees, or "sea turtles," to head the new centers and help them get the lay of the land. Now, MNCs may soon be partnering - or competing - with these same sea turtles who have switched gears to become China's newest entrepreneurs
Asia Spotlight: Ascendancy Healthcare CEO Sandy Zweifach On The Gap In China
Seeing a gap between the large infrastructure being built in China by multinational and domestic companies, Ascendancy hopes to be an interface to help China access drugs from the West.
Ascendancy Healthcare CEO Sandy Zweifach On The Gap In China: An Interview With PharmAsia News (Part 2 of 2)
Seeing a gap between the large infrastructure being built in China by multinational and domestic companies, Ascendancy hopes to be an interface to help China access drugs from the West.